# Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

Source: https://onco.cc/trials/nct07195591/  
OnCo record `nct07195591` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Temozolomide in glioma & glioblastoma, run by GT Medical Technologies, Inc., now recruiting.

## Summary

Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care is a phase 3 interventional study registered as NCT07195591 by GT Medical Technologies, Inc., with 766 participants planned, started 2025-12-10 and due to reach its primary completion in 2031-12. Interventions recorded: GammaTile®, External Beam Radiation Therapy and Temozolomide.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07195591
- Phase: 3
- Setting: Randomized Study of Resection and GammaTile® Followed by Concurrent External Beam Radiation Therapy (EBRT) and Temozolomide (TMZ) and Adjuvant TMZ Versus Standard of Care in Newly Diagnosed Glioblastoma (GBM)
- Sponsor: GT Medical Technologies, Inc.
- Enrolled: 766

## Sources

- ClinicalTrials.gov NCT07195591: https://clinicaltrials.gov/study/NCT07195591

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [Temozolomide](https://onco.cc/drugs/temozolomide/)
- companies: [GT Medical Technologies](https://onco.cc/companies/gt-medical-technologies/)

---
JSON: https://onco.cc/api/v1/entities/nct07195591.json